Hepatitis/MASH

Cognitive impairment more prevalent in patients with HIV coinfection than in those with hepatitis C infection alone.

Successful treatment with buprenorphine is crucial for patients with opioid use disorder.

Glecaprevir is a NS3/4A protease inhibitor and pibrentasvir is a NS5A inhibitor for hepatitis C patients without cirrhosis.

Glecaprevir/pibrentasvir is indicated as an eight-week treatment for hepatitis C among patients without cirrhosis.

Company seeks to leverage technologies to address unmet needs.

Top news of the day from across the health care landscape.

This fixed-dose combination of sofosbuvir and velpatasvir is indicated to treat chronic HCV genotypes 1-6.

Novartis partners with Conatus to develop a new drug for non-alcoholic steatohepatitis.

Hepatitis A infection rates have decreased in the United States and are the lowest they have been in 40 years.

Combination drugs may cause adverse events in individuals coinfected with HIV and HCV.

Top articles of 2016 on Specialty Pharmacy Times.

Top HCV articles of the year on Specialty Pharmacy Times.

Study seeks the optimal drug combination for patients with HCV genotype 2 and cirrhosis.

Reovirus could treat liver diseases such as hepatitis C virus and primary liver cancer.

Over the years, a number of landmark clinical studies in virology have been published, shaping how we treat the disease today.

HCV patients without cirrhosis achieved SVR after 8 weeks of treatment with glecaprevir/pibrentasvir.

HCV patients without cirrhosis achieved SVR after 8 weeks of treatment with glecaprevir/pibrentasvir.

After 2 years of exclusion, Harvoni has been added to the Express Scripts national formulary for the treatment of hepatitis C.

The state’s health department recommends that patients be screened for HIV, and hepatitis B and C viruses.

Agreement will expand treatment options for patients with hepatitis C.

Pennsylvania health department recommends that patients be screened for HIV, and hepatitis B and C viruses.

Jury declares Merck’s acquired HCV drug patent valid.

Assistance program will provide financial assistance for FDA-approved HCV drugs.

Sofosbuvir/ribavirin treatment is typically prescribed for 12 weeks, but for some patients with hepatitis C virus, a longer duration may be needed.

Portal hypertension creates problems in patients coinfected with HIV and hepatitis C virus.